

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

[f Share](#)

[t Tweet](#)

[in LinkedIn](#)

[✉ Email](#)

[🖨 Print](#)

[Home](#) | [Back to Product Details](#)

Additional Information about Patents

- Patent information is published on or after the submission date as defined in 21 CFR 314.53(d)(5).
- Patent listings published prior to August 18, 2003, only identify method-of-use claims. The listed patents may include drug substance and/or drug product claims that are not indicated in the listing.
- As of December 5, 2016, an NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that it claims either the drug substance or the drug product. Orange Book users should not rely on an Orange Book patent listing, regardless of when first published, to determine the range of patent claims that may be asserted by an NDA holder or patent owner.

Patent and Exclusivity for: N215866

Product 002
TIRZEPATIDE (MOUNJARO (AUTOINJECTOR)) SOLUTION 5MG/0.5ML (5MG/0.5ML)

Patent Data

Product No	Patent No	Patent Expiration	Drug Substance	Drug Product	Patent Use Code	Delist Requested	Submission Date
002	9474780	01/05/2036	DS	DP	U-3378		06/09/2022
002	11357820	06/14/2039		DP			06/30/2022
002	12295987	12/30/2041			U-4192 U-4193		06/11/2025
002	12343382	07/22/2039			U-4229 U-4230 U-4231 U-4232		07/25/2025

Exclusivity Data

Product No	Exclusivity Code	Exclusivity Expiration
002	NCE	05/13/2027

[View a list of all patent use codes](#)
[View a list of all exclusivity codes](#)

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

[f Share](#)

[t Tweet](#)

[in LinkedIn](#)

[✉ Email](#)

[🖨 Print](#)

[Home](#) | [Back to Product Details](#)

Additional Information about Patents

- Patent information is published on or after the submission date as defined in 21 CFR 314.53(d)(5).
- Patent listings published prior to August 18, 2003, only identify method-of-use claims. The listed patents may include drug substance and/or drug product claims that are not indicated in the listing.
- As of December 5, 2016, an NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that it claims either the drug substance or the drug product. Orange Book users should not rely on an Orange Book patent listing, regardless of when first published, to determine the range of patent claims that may be asserted by an NDA holder or patent owner.

Patent and Exclusivity for: N215866

Product 002

TIRZEPATIDE (MOUNJARO (AUTOINJECTOR)) SOLUTION 5MG/0.5ML (5MG/0.5ML)

Patent Data

Product No	Patent No	Patent Expiration	Drug Substance	Drug Product	Patent Use Code	Delist Requested	Submission Date
002	9474780	01/05/2036	DS	DP	U-3378		06/09/2022
002	11357820	06/14/2039		DP			06/30/2022
002	12295987	12/30/2041			U-4192 U-4193		06/11/2025
002	12343382	07/22/2039			U-4229 U-4230 U-4231 U-4232		07/25/2025

Exclusivity Data

Product No	Exclusivity Code	Exclusivity Expiration
002	NCE	05/13/2027

[View a list of all patent use codes](#)
[View a list of all exclusivity codes](#)

[FDA Archive](#)

[About FDA](#)

[Accessibility](#)

[Visitor Information](#)

[Website Policies / Privacy](#)

[No FEAR Act](#)

[Vulnerability Disclosure Policy](#)

[FOIA](#)

[HHS.gov](#)

[USA.gov](#)

Contact FDA



1-888-INFO-FDA (1-888-463-6332)